deltatrials
Recruiting PHASE2 INTERVENTIONAL 2-arm NCT07036380

MP0317 in Combination With Chemoimmunotherapy in First Line Treatment for Patients With Advanced Biliary Tract Carcinoma (TACTIC)

MP0317, a Tumor Targeting FAP Dependent CD40 Agonist DARPin, in Combination With Chemoimmunotherapy in First Line Treatment for Patients With Advanced Biliary Tract Carcinoma: a Radnomized Non-comparative Proof of Concept Phase II Study

Sponsor: Centre Hospitalier Universitaire de Besancon

Conditions Advanced Biliary Tract Carcinoma
Interventions CT-Scan Gemcitabine + Cisplatin + Durvalumab MP0317 + Gemcitabine + Cisplatine + Durvalumab
Updated 3 times since 2025 Last updated: Jan 7, 2026 Started: Dec 22, 2025 Primary completion: Nov 30, 2028 Completion: Nov 30, 2029
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Advanced Biliary Tract Carcinoma and is currently actively recruiting participants. Centre Hospitalier Universitaire de Besancon leads this study, which shows 3 recorded versions since 2025 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jul 2025 – ~Sep 2025 · 2 months · monthly snapshotNot Yet Recruiting~Sep 2025 – ~Feb 2026 · 5 months · monthly snapshotNot Yet Recruiting~Feb 2026 – present · 5 months · monthly snapshotRecruiting

Change History

3 versions recorded

  1. Feb 2026 — Present [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  2. Sep 2025 — Feb 2026 [monthly]

    Not Yet Recruiting PHASE2

  3. Jul 2025 — Sep 2025 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Centre Hospitalier Universitaire de Besancon
  • Molecular Partners AG
Data source: Centre Hospitalier Universitaire de Besancon

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations